Previous 10 | Next 10 |
2024-05-08 06:33:25 ET More on Veru Veru Inc. (VERU) Q1 2024 Earnings Call Transcript Veru Q2 2024 Earnings Preview Veru gets Nasdaq notice related to delayed quarterly report on form 10-Q Seeking Alpha’s Quant Rating on Veru Historical earning...
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy ® * ) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical,...
2024-05-07 12:06:40 ET More on Veru Veru Inc. (VERU) Q1 2024 Earnings Call Transcript Veru gets Nasdaq notice related to delayed quarterly report on form 10-Q Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial info...
2024-05-03 14:00:03 ET Yi Chen from H.C. Wainwright issued a price target of $3.00 for VERU on 2024-05-03 11:38:00. The adjusted price target was set to $3.00. At the time of the announcement, VERU was trading at $1.67. The overall price target consensus is at $11.50 wit...
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced tha...
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it ...
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline clinical data expected in the fourth quarter calendar year 2024 -- MIAMI, FL, April 30, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical ...
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced t...
2024-04-19 08:16:20 ET Losers: Tritium DCFC Limited ( DCFC ) -59% . Nexalin Technology ( NXL ) -29% . Moolec Science ( MLEC ) -17% . AGBA Group Holding Limited ( AGBA ) -15% . INVO Bioscience ( INVO ) -11% . Iczoom Group ( ...
2024-04-18 10:00:26 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among m...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...